Imbruvica (ibrutinib) – MIMS – New risk minimisation measures

This article was produced by the HPRA for publication in the April edition of Monthly Index of Medical Specialties (MIMS) and describes new risk minimisation measures, including dose modification recommendations, due to increased risk of serious cardiac events associated with the use of Imbruvica (ibrutinib).